Prognostic value of activin A level in patients with advanced lung cancer and sarcopenia

Authors

DOI:

https://doi.org/10.14739/2409-2932.2024.1.293093

Keywords:

activins, sarcopenia, lung adenocarcinoma, survival

Abstract

The aim of this work is to determine the prognostic role of activin A in patients with advanced lung cancer and sarcopenia.

Materials and methods. Forty patients with advanced pulmonary adenocarcinoma who received treatment in the medical center “ONCOLIFE” from 2020 to 2022 were studied. Computed tomography (CT) was used to measure skeletal muscle index at the third lumbar vertebra level expressed in cm2/m2. The criteria for sarcopenia using CT was <55 cm2/m2 for men and <39 cm2/m2 for women. Determination of activin A (DAC00B, RnD Systems) was carried out by the immunoenzymatic method based on using the “sandwich” variant of solid-phase immunoenzymatic analysis.

Results. Overall survival in patients with a high level of activin A was worse than in patients with a low level (22.7 % vs. 64.2 % respectively; p = 0.017 by the log-rank test).

Conclusions. A high level of activin A in the blood plasma can contribute to the worsening of the severity of sarcopenia, thereby affecting the survival of cancer patients. Understanding and finding new molecular targets underlying muscle atrophy will help identify new potential for treating patients with advanced cancer.

Author Biography

V. V. Kechedzhyiev, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD student of the Department of Oncology and Surgical Oncology

References

Anjanappa M, Corden M, Green A, Roberts D, Hoskin P, McWilliam A, Choudhury A. Sarcopenia in cancer: Risking more than muscle loss. Tech Innov Patient Support Radiat Oncol. 2020;16:50-7. doi: https://doi.org/10.1016/j.tipsro.2020.10.001

Hilmi M, Jouinot A, Burns R, Pigneur F, Mounier R, Gondin J, et al. Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology? Pharmacol Ther. 2019;196:135-59. doi: https://doi.org/10.1016/j.pharmthera.2018.12.003

Loumaye A, de Barsy M, Nachit M, Lause P, van Maanen A, Trefois P, et al. Circulating Activin A predicts survival in cancer patients. J Cachexia Sarcopenia Muscle. 2017;8(5):768-77. doi: https://doi.org/10.1002/jcsm.12209

Daitoku N, Miyamoto Y, Hiyoshi Y, Tokunaga R, Sakamoto Y, Sawayama H, et al. Activin A promotes cell proliferation, invasion and migration and predicts poor prognosis in patients with colorectal cancer. Oncol Rep. 2022;47(6):107. doi: https://doi.org/10.3892/or.2022.8318

Lyu S, Jiang C, Xu R, Huang Y, Yan S. INHBA upregulation correlates with poorer prognosis in patients with esophageal squamous cell carcinoma. Cancer Manag Res. 2018;10:1585-96. doi: https://doi.org/10.2147/CMAR.S160186

Zhong X, Pons M, Poirier C, Jiang Y, Liu J, Sandusky GE, et al. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J Cachexia Sarcopenia Muscle. 2019;10(5):1083-101. doi: https://doi.org/10.1002/jcsm.12461

Gomez-Perez S, McKeever L, Sheean P. Tutorial: A Step-by-Step Guide (Version 2.0) for Measuring Abdominal Circumference and Skeletal Muscle From a Single Cross-Sectional Computed-Tomography Image Using the National Institutes of Health ImageJ. JPEN J Parenter Enteral Nutr. 2020;44(3):419-24. doi: https://doi.org/10.1002/jpen.1721

Paajanen J, Ilonen I, Lauri H, Järvinen T, Sutinen E, Ollila H, et al. Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy. Clin Lung Cancer. 2020;21(3):e142-e150. doi: https://doi.org/10.1016/j.cllc.2019.10.013

Bauer J, Emon MAB, Staudacher JJ, Thomas AL, Zessner-Spitzenberg J, Mancinelli G, et al. Increased stiffness of the tumor microenvironment in colon cancer stimulates cancer associated fibroblast-mediated prometastatic activin A signaling. Sci Rep. 2020;10(1):50. doi: https://doi.org/10.1038/s41598-019-55687-6

Ries A, Schelch K, Falch D, Pany L, Hoda MA, Grusch M. Activin A: an emerging target for improving cancer treatment? Expert Opin Ther Targets. 2020;24(10):985-96. doi: https://doi.org/10.1080/14728222.2020.1799350

Downloads

Published

2024-02-23

How to Cite

1.
Kechedzhyiev VV. Prognostic value of activin A level in patients with advanced lung cancer and sarcopenia. Current issues in pharmacy and medicine: science and practice [Internet]. 2024Feb.23 [cited 2024Apr.27];17(1):44-7. Available from: http://pharmed.zsmu.edu.ua/article/view/293093

Issue

Vol. 17 No. 1 (2024): Current issues in pharmacy and medicine: science and practice

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.     Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)